MannKind (MNKD) Matches Q3 Earnings Estimates
MannKind (MNKD) came out with quarterly earnings of $0.04 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.02 per share a year ago.
MannKind Corporation (MNKD) Hits Fresh High: Is There Still Room to Run?
MannKind (MNKD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why MannKind (MNKD) Could Beat Earnings Estimates Again
MannKind (MNKD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
MannKind (MNKD) Just Overtook the 20-Day Moving Average
MannKind (MNKD) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MNKD broke through the 20-day moving average, which suggests a short-term bullish trend.
MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion
MannKind's stock has surged 73%, driven by its 9% royalty stake in United Therapeutics' Tyvaso DPI, which excels in the PAH market. In Q2 2024, MannKind's revenues rose 49% year-over-year to $72 million, largely due to Tyvaso DPI royalties and manufacturing income. MannKind is advancing a promising pipeline, including MNKD 101 and Nintedanib DPI, aimed at addressing unmet needs in orphan lung diseases.
Is MannKind (MNKD) Stock Outpacing Its Medical Peers This Year?
Here is how MannKind (MNKD) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.
MannKind Corporation (MNKD) Q2 2024 Earnings Call Transcript
MannKind Corporation (NASDAQ:MNKD ) Q2 2024 Earnings Conference Call August 7, 2024 9:00 AM ET Company Participants Michael Castagna - CEO Chris Prentiss - CFO Conference Call Participants Olivia Brayer - Cantor Fitzgerald Thomas Smith - Leerink Partners Gregory Renza - RBC Capital Markets Brandon Folkes - Rodman & Renshaw Operator Good morning and welcome to the MannKind Corporation Second Quarter 2024 Financial Results Earnings Call. As a reminder, this call is being recorded August 7, 2024 and will be available for playback on the MannKind Corporation website shortly after the conclusion of this call and available for approximately 90 days.
MannKind (MNKD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
MannKind (MNKD) Q2 Earnings and Revenues Surpass Estimates
MannKind (MNKD) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to break-even earnings per share a year ago.
All You Need to Know About MannKind (MNKD) Rating Upgrade to Buy
MannKind (MNKD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is MannKind (MNKD) Outperforming Other Medical Stocks This Year?
Here is how MannKind (MNKD) and Merck (MRK) have performed compared to their sector so far this year.
MannKind Corporation (MNKD) Hit a 52 Week High, Can the Run Continue?
MannKind (MNKD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
